Figure 2From: A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell diseasePatient distribution. A total of 62 patients were randomly assigned to treatment (prasugrel [41], placebo [21]) and were included in the Intent-to-Treat (ITT) analysis setBack to article page